Merck to acquire Sigma-Aldrich for $140 per share in cash, valuing company at approx. $17 billion (€13.1 billion) Acquisition expands Merck Millipore’s global reach, ...

German pharma company Merck is to pay $17 billion to acquire Sigma-Aldrich, a specialist in chemicals, kits and services used in life sciences research. Headquartered in Damstadt, Merck is a ...

The Sigma-Aldrich acquisition is now Merck’s largest deal ever, eclipsing the €10.3 billion ($13.2 billion) acquisition of the former Swiss-based biotech Serono SA in 2007.

Drugs and chemicals maker Merck KGaA <MRCG.DE> agreed on Monday to acquire U.S.-based Sigma-Aldrich Corp <SIAL.O> for $17 billion in cash to boost its lab supplies business, the biggest takeover ...

German chemical manufacturer Merck KGaA said Monday it agreed to buy Sigma-Aldrich for about $17 billion to expand its business in North America and gain exposure in Asia. Merck KGaA is paying ...

FRANKFURT, Sept 22 (Reuters) - Drugs and chemicals maker Merck KGaA agreed on Monday to acquire U.S. company Sigma-Aldrich for $17 billion in cash to boost its lab supplies business, the biggest ...

Sigma-Aldrich, on Sep 22, 2014, announced that Merck KGaA has agreed to buy it for $17 billion. Under the deal terms, Merck KGaA will buy all of the outstanding shares of Sigma-Aldrich for $140 ...

Merck and Sigma-Aldrich have entered into a definitive agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion (€13.1 billion), establishing one of the leading players in the $130 ...

Sigma-Aldrich employs more than 9,000 worldwide, including 1,800 in St. Louis. Germany's Merck to buy Sigma-Aldrich for $17 billion Skip to main content Skip to main content ...

Merck to acquire Sigma-Aldrich for $140 per share in cash, valuing company at approx. $17 billion. Acquisition expands Merck Millipore’s global reach, increasing the company’s presence in North ...

Germany's Merck is paying $17 billion to acquire Sigma-Aldrich, a U.S. supplier of laboratory testing materials, as Merck looks to reduce its reliance on finding blockbuster drugs.